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ObesityAbstract Background: This study evaluates the correlation between body mass index (BMI) and
clinicopathological parameters of metastatic prostate cancer (MPC) and its impact on survival.
Method: During the study period, 71 MPC patients were eligible. Patients with BMI < 25.0 kg/m2
were categorized as level I and patients with BMIP 25.0 kg/m2 were categorized as level II.
Demographic features and survival rates were evaluated by the Kaplan–Meier method and Cox
proportional models.
Results: 31 patients belonged to level I while the rest belonged to level II with insigniﬁcant higher
median follow-up duration in level II; p= 0.5. In terms of age, metastasis, serum level of albumin,
prostatic speciﬁc antigen, alkaline phosphatase (AKP) and Gleason score, there was no signiﬁcant
difference between the two levels. The cumulative survival probability in the 12th, 24th and 36th
month in level I vs; level II was; 86.7%, 68.7%, 64.1% vs; 74.4%, 67.7%, 55.1%, respectively with
7 patients dead in level I compared to 14 patients dead in level II denoting a higher PC-speciﬁc
death rate in the level II group.
In univariate and multivariate analysis, poor prognosis was associated with increasing AKP
(HR= 1.0005, 95% CI, p= 0.03; HR= 1.001, 95% CI, p= 0.03) respectively, while better
prognosis was associated with no visceral metastasis (HR = 0.09, 95% CI, p= 0.000;
HR= 0.04, 95% CI, p= 0.000) and increasing albumin levels (HR= 0.17, 95% CI, p= 0.000;
156 A.A. Mohammed et al.HR= 0.15, 95% CI, p= 0.000) respectively. In multivariate analysis only, patients belonging to
level I were associated with better prognosis (HR= 0.17, 95% CI, p= 0.02).
Conclusion: BMI is dependent on prognostic factors in patients with MPC.
ª 2015 National Cancer Institute, Cairo University. Production and hosting by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Prostate cancer (PC) has surpassed lung cancer as the most
commonly diagnosed cancer in men. An estimated 230,000
new cases were diagnosed in 2014, accounting for 27% of
new cancer cases in men [1].
Although 80–90% of PC with metastatic lesions responds
to initial androgen ablation therapy, most of these patients
ultimately develop progressive disease of hormone refractory
cancer [2].
Obesity, as a growing epidemic all over the world, has been
linked to mortality of several cancers [3]. Only in the past 5 to
10 years, BMI as a surrogate of adiposity has been evaluated
for PC incidence, but the relation between BMI and aggressive
PC is still not fully evaluated [4].
An epidemiologic study reported that obesity may be
protective against the development of early stage PC. On the
contrary, other studies have shown that obesity may be
associated with an increased risk of advanced disease and
death from PC [5].
Amling et al. reported higher rates of positive surgical
resection margins and biochemical recurrence in obese patients
with localized PC undergoing radical prostatectomy than in
normal-weight patients, which are considered to be a represen-
tative example of an association between obesity and localized
PC [6].
To our knowledge, studies are still lacking on the relation
between BMI and metastatic prostate cancer (MPC).
The aim of the current study is to assess the relation
between BMI, clinicopathological parameters and the outcome
of MPC.
Materials and methods
The current retrospective cohort design included 71 MPC
patients during the period from January 2011 to March 2015
who were diagnosed and treated in King Abdullah Medical
City (KAMC) and 7 were excluded due to incomplete data.
The eligibility criteria were; histological conﬁrmed PC, evi-
dence of metastatic disease, by use of the medical records of
the patients, the demographic data including age at time of
diagnosis, pathological features, serum prostatic speciﬁc anti-
gen (PSA) level, Gleason score, serum AKP, serum LDH,
complete blood count, liver proﬁle, renal proﬁle, metastasis
to the internal organs, and follow-up period were investigated
retrospectively. BMI was calculated at the time of diagnosis,
we used measured weight and height to calculate BMI
(kg/m2). According to the World Health Organization
Guidelines, Patients were classiﬁed into 2 levels: patients with
BMI (<25 kg/m2) were categorized as level I and patients with
BMI (P25 kg/m2) were categorized as level II.Clinicopathologic and outcome data were tested for its relation
with BMI.
Statistical analysis
Data were analyzed by using SPSS version 17 (SPSS Inc.,
Chicago, IL, USA) and has been subjected to descriptive anal-
ysis. The variables like subjects; visceral metastasis, lymph
node involvement, bone metastasis, life status, and BMI, i.e.,
(<25 and P25) were taken as binary nominal variables. On
the other hand, age, serum levels of; prostatic speciﬁc antigen
PSA, AKP, lactate LDH and duration in months from the
start of treatment to death or last follow up were taken as con-
tinuous variables. Categorical variables have been expressed as
n (%), undergone cross tabulation and compared by Chi-
square or Fisher exact test where appropriate. Continuous
data were subjected to normality testing by the Shapiro–
Wilk test and expressed as mean ± standard deviation (SD)
or median (minimum–maximum). Continuous data were com-
pared by using Student’s t test or Mann Whitney U test after
determining the normality. Time to death was assessed using
survival analysis (Kaplan–Meier curve) and the differences in
survival distributions for BMI categories were evaluated via
Log Rank (Mantel-Cox) test. Moreover, the analysis is further
supported by mean survival time with 95% conﬁdence interval
along with cumulative survival probability at different points
in time. Univariate as well as multivariate Cox proportional
hazards model has been used to estimate hazard ratios
(HRs) and 95% conﬁdence interval for deaths due to meta-
static prostate cancer from all predictors by using the time
duration in months since the treatment started. An alpha level
of <0.05 has been considered signiﬁcant for each analysis.
Results
A total of 71 patients were included in the study, according to
subjects’ BMI level, 31 patients (43.7%) belonged to level I
while the rest belonged to level II. Though median follow up
duration appeared to be longer in level II BMI, than level I
yet not signiﬁcant, 20.4 (0.1–44.1) months vs; 14.3 (2.1–36.6)
months respectively, p= 0.5. In addition, there were no signif-
icant differences between the two levels in terms of age, visceral
metastasis, bone metastasis, serum levels of albumin, PSA,
AKP and degree of differentiation (Gleason score). However,
serum LDH levels were signiﬁcantly higher in level II subjects
than the level I group, i.e., median (range) 212 (47–1937) than
163 (65–4575), p= 000, respectively (Table 1).
The cumulative survival probabilities in 12th, 24th and 36th
month of the level I and level II groups were; 86.7%, 68.7%,
64.1% and 74.4%, 67.7%, 55.1%, respectively. In the level I
group, 7 patients died of PC, while in the level II group, 14
Table 1 Patients’ characteristics according to BMI.
Parameters Body mass index (kg/m2) N p-Value
Level I Level II
Patients numbers (%) 31 (43.7%) 40 (56.3%) 71 (100%) 0.3
Age (years) 72.2 ± 9.1 71.9 ± 8.6 72 ± 8.7 0.8
Poorly diﬀerentiated Pathology (Gleason score 8–10) (yes) 10 (32.3%) 15 (37.5%) 25 (35.2%) 0.6
Visceral metastasis (yes) 6 (19.4%) 12 (30%) 18 (25.4%) 0.3
Bone metastasis (yes) 23 (74.2%) 35 (87.5%) 58 (81.7%) 0.2
Prostatic speciﬁc antigen 39 (1–2715) 66.3 (0.1–16,430) 54 (0.1–16,430) 0.7
Albumin 3.2 ± 0.5 3.3 ± 0.7 3.2 ± 0.6 0.7
Lactate dehydrogenase (U/L) 163 (65–4575) 212 (47–1937) 187 (47–4575) 0.00
Alkaline phosphatase (U/I) 103 (42–4940) 109.5 (48–3280) 107 (42–4940) 0.6
Follow up (months) 14.3 (2.1–36.6) 20.4 (0.1–44.1) 14.4 (0.1–44.1) 0.7
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rate in the level II group than the level I group (Fig. 1).
In the Univariate Cox-proportional hazard model, poor
prognosis was associated with increasing serum AKP
(HR= 1.0005, 95% CI 1.0005–1.001, p= 0.03) and serum
LDL (1.001, 95% CI 1.0002–1.001, p= 0.01) levels while bet-
ter prognosis was associated with no visceral metastasis
(HR= 0.09, 95% CI 0.03–0.2, p= 0.000) and increasing
serum albumin level (HR= 0.17, 95% CI 0.09–0.34,
p= 0.000) (Table 2).
In the Multivariate Cox-proportional hazard model, poor
prognosis was associated with increasing serum AKP level
(HR= 1.001, 95% CI 1.0001–1.002, p= 0.03) while better
prognosis was associated with no visceral metastasis
(HR= 0.04, 95% CI 0.008–0.2, p= 0.000), increasing serum
albumin level (HR= 0.15, 95% CI 0.05–0.4, p= 0.000) and
BMI < 25 (HR= 0.17, 95% CI 0.04–0.7, p= 0.02).
Discussion
Obesity is a major health problem throughout the world,
which has been linked to the development of variousFigure 1 Kaplan–Meier survival curves demonstrating patients’
cancer-speciﬁc survival for metastatic prostate cancer on the basis
of body mass index. BMI, body mass index.malignant diseases, including colorectal cancer, breast cancer
and PC [7]. Conversely, the relationship between PC and
obesity is still a matter of debate [8].
The ﬁndings reported in the present study that provide
better prognosis were associated with BMI < 25 kg/m2. In
the multivariate analysis, serum AKP levels, serum albumin
levels, visceral metastasis, and BMI < 25 kg/m2 were reported
as signiﬁcant prognostic factors with cumulative survival prob-
ability in 10, 20 and 30 months favoring low BMI < 25 kg/m2.
These results are consistent with many previous studies.
Rodriguez et al. [9] found PC mortality rates to be signiﬁcantly
higher among obese men.
Efstathiou et al. [10] reported greater baseline BMI is
independently associated with higher PC-speciﬁc mortality in
men with locally advanced PC. According to Gong et al.
[11], obesity at the time of diagnosis was associated with
increased risks of PC metastasis and death. In a prospective
cohort study on 5313 men who underwent radical prostatec-
tomy, Siddiqui et al. [12] demonstrated worse clinical and
pathologic features in patients with a higher BMI. There are
additional studies concluding the same results [13–16].
On the other hand, our results contradict some studies that
reported better effects of obesity on PC. A retrospective study
was conducted of 55 patients who were diagnosed with
castration-resistant prostate cancer (CRPC) and received
docetaxel treatment between 2003 and 2009. The ﬁndings
suggested that BMI as well as other prognostic factors are
independent prognostic factors in patients with CRPC who
receive docetaxel treatment, with improvement in cancer speci-
ﬁc survival rate in patients with high BMI [17]. In another
study Strom et al validated the importance of obesity in PC
progression and biochemical failure in patients treated with
external beam radiotherapy [18].
Moreover, a similar result was reported by Halabi et al. [19]
of a total of 1,226 patients with CRPC, the overall survival
rate and cancer-speciﬁc survival rate of overweight and obese
patients were higher than those of the normal-weight patients.
Several possible explanations have been proposed to clarify
the correlation between PC and obesity, hormonal and meta-
bolic changes are the primary concern. First is that certain
obesity-related metabolic dysregulation such as hyperinsuline-
mia and/or hypoadiponectinemia favors aggressive neoplastic
behavior [20,21].
Second is the association between lower levels of
testosterone in obese men and the poorly differentiated and
hormone insensitive tumors [22,23].
Table 2 Factors affecting cancer-speciﬁc survival in patients with MPC; Multivariate and univariate analyses.
Multivariate Cox regression hazard model Univariate Cox regression hazard model
HR 95.0% CI p value HR 95.0% CI p value
Lower Upper Lower Upper
Age 1.029 0.939 1.128 0.544 1.039 0.990 1.090 0.12
PSA 1.000 0.999 1.000 0.566 1.000 1.000 1.000 0.89
AKP 1.001 1.000 1.002 0.027 1.000 1.00005 1.001 0.025
Visceral metastasis No vs; yes 0.038 0.008 0.193 0.000 0.085 0.033 0.217 0.000
Bone No vs; yes 0.434 0.043 4.399 0.480 0.206 0.028 1.537 0.123
LDH 1.000 0.999 1.001 0.585 1.001 1.0002 1.001 0.013
Albumin 0.150 0.053 0.428 0.000 0.174 0.087 0.346 0.000
Poorly diﬀerentiated Pathology No vs; yes 8.1 0.8 79.3 0.071 0.8 0.33 2 0.66
BMI Level I vs; level II 0.168 0.039 0.728 0.017 0.692 0.274 1.748 0.436
HR, hazard ratio; CI, conﬁdence interval; BMI, body mass index; PSA, prostate speciﬁc antigen; LDH, Lactate dehydrogenase; AKP, Alkaline
phosphatase. Values < 0.05 were considered to indicate statistical signiﬁcance. Poorly differentiated pathology, Gleason score 8–10.
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free IGF-1, which is found to stimulate growth of prostate cell
lines in vitro and be more closely related to advanced stage PC
in humans [24]. Moreover, the delayed diagnosis and more
advanced stage in obese men are due to lower accuracy of dig-
ital rectal examination in obese men and lower PSA values
caused by obesity-related hemodilution [25,26].
A hypothesis is that the high mortality rates among those
with low BMI values could be due to systemic weight loss in
response to disease.
We should not forget that the presence of other studies have
shown no relationship between these two factors [27–29].
Limitations
Retrospective studies almost always are criticized as the com-
pleteness of data is often suboptimal and depends totally on
medical documentation beside the small sample size in the pre-
sent study. Unfortunately the data on smoking and competing
risk factors that may distort the relation between excess BMI
and PC mortality are not available. Despite this limitation,
for our knowledge, this is the ﬁrst such study in this ﬁeld in
King Saudi Arabia.
Conclusion & recommendation
Our data suggest that BMI is a dependent prognostic factor in
patients with MPC. The cumulative survival probability was
observed to improve more in patients with low BMI.
In addition, serum AKP level, serum LDL, serum albumin
and visceral metastasis are independent prognostic factors.
Further prospective and large-scale multi-institutional stud-
ies are needed to evaluate the role of BMI measured before, at,
or after PC diagnosis. Also, evaluation of genetic and
biomarkers related to adiposity can guide the development
of effective and targeted cancer prevention and therapeutic
options.
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